ResMed beats EPS by 13% as analysts lift targets
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
ResMed beat statutory profit expectations by 13% with first-quarter EPS of US$2.92, while revenue of US Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context